Trial Profile
A Randomized, Double-blind, Parallel-controlled Comparative Study to Evaluate the PK Pharmacokinetic Similarity After Single Administration of GB222 and Bevacizumab in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Genor Biopharma
- 21 Nov 2019 Planned End Date changed from 30 Nov 2017 to 1 Nov 2020.
- 21 Nov 2019 Planned primary completion date changed to 1 Aug 2020.
- 18 Apr 2017 New trial record